BackBioCardia - Warrants (26/07/2022) Overview
BioCardia Inc. - Warrants (26/07/2022)

BioCardia - Warrants (26/07/2022) Return on Equity

BioCardia - Warrants (26/07/2022) (BCDAW) has a ROE of -271.81%, below the Healthcare sector average of 21.67%.

Get informed when a big investor buys or sells

+ Follow

ROE

-271.81%

Return on Equity

-271.81%

Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.

ROE (Comparison Companies)

Loading

ROE History

Loading

ROE Comparison

Loading

BioCardia - Warrants (26/07/2022) (BCDAW) FAQ

The latest ROE for BCDAW is -271.81%. That is below the Healthcare sector average of 21.67%. Investors often review this figure alongside BioCardia - Warrants (26/07/2022)'s historical trend and sector peers before judging valuation or financial health.

Against Healthcare companies, BCDAW currently prints -271.81% for ROE, while the sector average sits near 21.67%. That is roughly 1354.4% below the sector mean. Large gaps often invite a closer look at BioCardia - Warrants (26/07/2022)'s growth, margins, and balance sheet.

Return on Equity shows how effectively BioCardia - Warrants (26/07/2022) converts resources into returns. At -271.81%, BCDAW may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting BCDAW's ROE (-271.81%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack BioCardia - Warrants (26/07/2022)'s ROE against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.